Livzon Pharmaceutical (SHE:000513, HKG:01513)

Executive Summary

Livzon Pharmaceutical Group is a leading Chinese integrated pharmaceutical company with over 30 years of history, focused on digestive diseases, psychiatry/neurology, assisted reproduction, autoimmune disorders, and other therapeutic areas. The company leverages proprietary long-acting microsphere and biopharmaceutical platforms, offering a diversified portfolio of chemical drugs, biologics, and traditional Chinese medicine. Listed on both Shenzhen and Hong Kong stock exchanges (SHE:000513, HKG:01513), Livzon has built a strong commercial presence in China and is expanding its pipeline in innovative therapies. Financially, Livzon benefits from steady revenue from established products and growing contributions from new launches. Key growth drivers include the ramp-up of its long-acting injectable franchise, potential approvals in autoimmune diseases, and increased penetration in assisted reproduction. The company maintains a robust R&D pipeline targeting high-unmet needs, with several assets in late-stage development. Despite pricing pressures in China, Livzon's diversified portfolio and technological moat position it for sustainable growth. Upcoming catalysts, including new drug approvals and pivotal data readouts, are expected to further strengthen its competitive positioning.

Upcoming Catalysts (preview)

• Q3 2026NMPA approval of long-acting microsphere formulation for schizophrenia70% success
• Q4 2026Phase 3 top-line data for IL-17 inhibitor in psoriasis60% success
• Q1 2027NDA submission for assisted reproduction drug in China50% success